Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib
Acquired thrombotic thrombocytopenic purpura (TTP) is characterized by autoantibodies against a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). Uncleaved von Willebrand factor (VWF) multimers accumulate and bind to platelets which causes spontaneous microt...
Saved in:
Main Authors: | Manu R. Pandey, Pankit Vachhani, Evelena P. Ontiveros |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-01-01
|
Series: | Case Reports in Hematology |
Online Access: | http://dx.doi.org/10.1155/2017/9681832 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
by: Claudio Cerchione, et al.
Published: (2016-01-01) -
Marked Improvement in Refractory TTP Directly after H. pylori Eradication Therapy
by: Irina Gringauz, et al.
Published: (2016-01-01) -
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma
by: Lawrence G Lum, et al.
Published: (2025-01-01) -
T-Cell Lymphoblastic Leukemia/Lymphoma: Relapse 16 Years after First Remission
by: Lauren Elreda, et al.
Published: (2014-01-01) -
Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era
by: Ayotola Fatola, et al.
Published: (2025-01-01)